相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
J. Kirchheiner et al.
PHARMACOGENOMICS JOURNAL (2007)
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD
David Michelson et al.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2007)
Pharmacogenetics of opioids
Andrew A. Somogyi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
M. E. E. Shams et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2006)
New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes
Li Li et al.
DRUG METABOLISM AND DISPOSITION (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Pharmacogenetics of antidepressants and antipsychotics:: the contribution of allelic variations to the phenotype of drug response
J Kirchheiner et al.
MOLECULAR PSYCHIATRY (2004)
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Codeine intoxication associated with ultrarapid CYP2D6 metabolism
Y Gasche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension
I Zineh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
UM Zanger et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study
C Kawanishi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
CYP2D6 genotype:: Impact on adverse effects and nonresponse during treatment with antidepressants -: A pilot study
T Rau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
J de Leon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects
H Wuttke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype:: a case-control study
I Schillevoort et al.
PHARMACOGENETICS (2002)
A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication
C Kawanishi et al.
CLINICAL GENETICS (2002)
Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
WH Chou et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
分享论文
